Targeting EGFR-positive NSCLC with antibody-drug conjugates

Jorge Nieva, MD, University of California, San Francisco, CA, comments on the promising role of antibody-drug conjugates (ADCs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). There are very limited options for patients who have progressed on third generation EGFR inhibitors, and ADCs represent a potential strategy for this group of patients. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.